Zacks Investment Research upgraded shares of Checkpoint Therapeutics (NASDAQ:CKPT) from a hold rating to a buy rating in a report issued on Thursday morning. They currently have $4.00 price objective on the stock.
According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “
Separately, HC Wainwright assumed coverage on Checkpoint Therapeutics in a research note on Friday, December 8th. They set a buy rating and a $11.00 price target for the company.
WARNING: “Checkpoint Therapeutics (CKPT) Upgraded to Buy at Zacks Investment Research” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3127292/checkpoint-therapeutics-ckpt-upgraded-to-buy-at-zacks-investment-research.html.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.